Results 251 to 260 of about 128,118 (293)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 1995
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Hematology, 2002
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
CONGENITAL MYELOGENOUS LEUKEMIA
Archives of Pediatrics & Adolescent Medicine, 1950Leukemia in the newborn is rare and unique in that it is almost invariably of the myelogenous type. Kelsey and Anderson,1in a comprehensive survey of the literature up to 1939, collected 17 reported cases of congenital leukemia. Of these, they accepted only 9 as instances of unquestionable congenital leukemia, the remaining 8 cases being probable ...
F M, TAYLOR, L J, GEPPERT
openaire +2 more sources
Current Problems in Pediatric and Adolescent Health Care, 2002
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
Clinical Journal of Oncology Nursing, 2005
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Cancer, 1978
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Smouldering Acute Myelogenous Leukemia
Acta Medica Scandinavica, 1978ABSTRACT. Among 195 patients with variants of acute myelogenous leukemia (AML), a minimum of 11 met our criteria of smouldering AML: patients with less than 30% of blast cells plus promyelocytes in the bone marrow at the time of diagnosis who were observed without specific antileukemic therapy for a period of at least 6 months without entering a ...
S A, Evensen, P, Stavem
openaire +2 more sources
Acute myelogenous leukemia heteroantisera
Clinical Immunology and Immunopathology, 1980Abstract Antisera were raised in New Zealand white rabbits to acute myelogenous leukemia (AML) cells. Reactivity of the antisera against normal T lymphocytes was eliminated by pretreating the rabbits with anti-leukocyte serum (ALS) and precoating the immunizing cell with ALS.
R, Billing +4 more
openaire +2 more sources